Literature DB >> 6318657

Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

B R Meyers, E S Srulevitch, J Jacobson, S Z Hirschman.   

Abstract

The pharmacokinetics of ceftriaxone were investigated in six healthy adults. One-gram doses were administered either intramuscularly or intravenously in a crossover design study. Mean peak ceftriaxone concentrations in plasma of 79.2 and 123.2 micrograms/ml were achieved with intramuscular injection and intravenous infusion, respectively, with plasma half-lives of 5.4 and 5.8 h. The urinary recovery of ceftriaxone in the first 24 h was 37% after intravenous infusion and 25% after intramuscular injection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318657      PMCID: PMC185948          DOI: 10.1128/AAC.24.5.812

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

2.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study.

Authors:  R Wise; A P Gillett; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  Pharmacokinetic parameters of sisomicin.

Authors:  B R Meyers; S Z Hirschman; S Yancovitz; B Ribner
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.

Authors:  K Shannon; A King; C Warren; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

10.  Pharmacokinetics of azlocillin in persons with normal and impaired renal functions.

Authors:  P Fiegel; K Becker
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more
  13 in total

1.  Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.

Authors:  Seulki Lee; Sang Kyoon Kim; Dong Yun Lee; Su Young Chae; Youngro Byun
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Spectrofluorimetric protocol for ceftriaxone in commercial formulation and human plasma after condensation with formaldehyde and ethyl acetoacetate.

Authors:  Jasmin Shah; M Rasul Jan; Sultan Shah; M Naeem
Journal:  J Fluoresc       Date:  2011-07-12       Impact factor: 2.217

4.  Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Authors:  Delphine Croisier-Bertin; Lionel Piroth; Pierre-Emmanuel Charles; Aurélie Larribeau; Donald Biek; Yigong Ge; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Economic forces and medical therapy of infective endocarditis.

Authors:  D Kaye
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

6.  Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates.

Authors:  Ok-Cheol Jeon; Seung Rim Hwang; Taslim A Al-Hilal; Jin Woo Park; Hyun Tae Moon; Seulki Lee; Jae Hyung Park; Youngro Byun
Journal:  Pharm Res       Date:  2013-01-05       Impact factor: 4.200

7.  Daily variations in ceftriaxone pharmacokinetics in rats.

Authors:  M Rebuelto; L Ambros; M Rubio
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults.

Authors:  H H Zhou; Y P Chan; K Arnold; M Sun
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

10.  Ceftriaxone pharmacokinetics following multiple intramuscular dosing.

Authors:  A A Holazo; I H Patel; R E Weinfeld; J J Konikoff; M Parsonnet
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.